SPERMOSENS AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1565 SEK | +2.29% |
|
-11.58% | -77.48% |
| 04-23 | Spermosens AB Appoints Tore Duvold as CEO, Effective May 1, 2024 | CI |
| 02-09 | Spermosens AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 214.4 | 22.51 | 28.63 |
| Enterprise Value (EV) 1 | 208.2 | 23.32 | 33.65 |
| P/E ratio | -28 x | -1.69 x | -2.17 x |
| Yield | - | - | - |
| Capitalization / Revenue | 17.2 x | 2 x | - |
| EV / Revenue | 16.7 x | 2.07 x | - |
| EV / EBITDA | - | -1,872,421 x | -3,144,115 x |
| EV / FCF | -12,820,507 x | -1,119,027 x | -1,799,014 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 9.07 x | 0.76 x | 2.26 x |
| Nbr of stocks (in thousands) | 10,511 | 12,116 | 41,194 |
| Reference price 2 | 20.40 | 1.858 | 0.6950 |
| Announcement Date | 4/14/22 | 4/14/23 | 4/18/24 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales 1 | 0.4101 | 2.338 | 12.49 | 11.25 | - |
| EBITDA | - | - | - | -12.45 | -10.7 |
| EBIT 1 | 0.0223 | -2.042 | -6.151 | -12.52 | -10.87 |
| Operating Margin | 5.44% | -87.36% | -49.25% | -111.27% | - |
| Earnings before Tax (EBT) 1 | 0.0223 | -2.045 | -6.423 | -12.65 | -12.2 |
| Net income 1 | 0.0168 | -2.045 | -6.423 | -12.65 | -12.2 |
| Net margin | 4.09% | -87.48% | -51.43% | -112.42% | - |
| EPS 2 | 0.008571 | -0.3904 | -0.7288 | -1.101 | -0.3204 |
| Free Cash Flow | - | -4.366 | -16.24 | -20.84 | -18.71 |
| FCF margin | - | -186.76% | -130.04% | -185.25% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/13/21 | 4/13/21 | 4/14/22 | 4/14/23 | 4/18/24 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | - | 1.79 | - | 0.81 | 5.03 |
| Net Cash position 1 | 0.51 | - | 6.2 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -0.0649 x | -0.4695 x |
| Free Cash Flow | - | -4.37 | -16.2 | -20.8 | -18.7 |
| ROE (net income / shareholders' equity) | - | -67.6% | -47.5% | -47.5% | -132% |
| ROA (Net income/ Total Assets) | - | -19.6% | -21.6% | -26.5% | -38% |
| Assets 1 | - | 10.41 | 29.75 | 47.75 | 32.11 |
| Book Value Per Share 2 | 1.340 | 0.6500 | 2.250 | 2.440 | 0.3100 |
| Cash Flow per Share 2 | 0.2600 | 0.7100 | 0.6400 | 0.0500 | 0.1100 |
| Capex | - | - | - | 0.78 | 0.11 |
| Capex / Sales | - | - | - | 6.91% | - |
| Announcement Date | 4/13/21 | 4/13/21 | 4/14/22 | 4/14/23 | 4/18/24 |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- SPERM Stock
- Financials Spermosens AB
